2-氯-1-(3-吡啶基)乙醇 | 174615-69-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-氯-1-(3-吡啶基)乙醇
• 英文名称: rac-2-chloro-1-(pyridin-3-yl)ethanol
• 英文别名: (+/-)-2-chloro-1-(3-pyridyl)-ethanol；2-chloro-1-(pyridin-3-yl)ethan-1-ol；(+/-)-3-(1-hydroxy-2-chloroethyl)-pyridine；2-Chloro-1-(pyridin-3-yl)ethanol；2-chloro-1-pyridin-3-ylethanol
• CAS: 174615-69-1
• 化学式: C₇H₈ClNO
• 分子量: 157.6
• InChiKey: LCBCRIBFOZSPJL-UHFFFAOYSA-N

物化性质

• 沸点：
  299.5±25.0 °C(Predicted)
• 密度：
  1.259±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-氯-1-(3-吡啶基)乙醇 生成 (S)-2-chloro-1-(pyridin-3-yl)ethanol 、 (R)-1-(3-吡啶基)-2-氯乙醇
  参考文献：
  名称：

  NOVEL SULFONAMIDE SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS

  摘要：

  公开号：

  EP1054881B1
• 作为产物：
  描述：

  2-氯-1-(吡啶-3-基)乙酮 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 以81%的产率得到2-氯-1-(3-吡啶基)乙醇
  参考文献：
  名称：

  Solvent and in situ catalyst preparation impacts upon Noyori reductions of aryl-chloromethyl ketones: application to syntheses of chiral 2-amino-1-aryl-ethanols

  摘要：

  As part of medicinal chemistry efforts we found it necessary to develop general syntheses of highly enantiomerically enriched 1-aryl-2-chloroethanols and 1-aryl-2-methylaminoethanols. A survey of literature methods suggested that a truly general approach had not yet been reported, encouraging us to undertake the development of such a methodology. This study describes the design, development, and reduction to practice of a general synthesis of chiral 1-aryl-2-chloroethanols and the transformation of these entities to highly enantiomerically enriched 1-aryl-2-methylaminoethanols. Of particular importance were observations of the impact of solvent and the method of catalyst preparation on the yield and enantiomerical excess of chlorohydrins prepared via Noyori transfer hydrogenations of aryl-chloromethyl ketones. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2006.07.017

文献信息

• 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists
  申请人：——

  公开号：US20030078260A1

  公开（公告）日：2003-04-24

  This invention relates to novel 2,6-substituted chroman derivatives which are useful in the treatment of beta-3 adrenoreceptor-mediated conditions.

  这项发明涉及新颖的2,6-取代的色苷衍生物，可用于治疗β-3肾上腺素受体介导的疾病。
• PROCESS FOR PREPARATION OF (S)-ALPHA-HALOME THYLPYRIDINE METHANOL DERIVATIVES
  申请人：KANEKA CORPORATION

  公开号：EP1454899A1

  公开（公告）日：2004-09-08

  The present invention provides a process for easily preparing a (S)-α-halomethylpyridine-methanol derivative, which is useful as an intermediate of pharmaceutical products, from inexpensive raw materials. The (S)-α-halomethylpyridine-methanol derivative is prepared by (S)-selectively reducing a 2-haloacetylpyridine derivative using an enzyme source having ability to (S)-selectively reduce a carbonyl group of the 2-haloacetylpyridine derivative, which can be obtained inexpensively. Also, a hydrohalic acid salt of (S)-α-halomethyl-3-pyridine-methanol derivative is isolated and purified as crystal from a (S)-α-halomethyl-3-pyridine-methanol derivative containing impurities using hydrohalic acid and an organic solvent.

  本发明提供了一种从廉价原料中轻松制备(S)-α-卤甲基吡啶-甲醇衍生物的方法，该衍生物可用作制药产品的中间体。该(S)-α-卤甲基吡啶-甲醇衍生物是通过使用具有(S)-选择性还原2-卤乙酰吡啶衍生物的羧酸还原酶源制备的，该酶源能够(S)-选择性地还原2-卤乙酰吡啶衍生物，而该酶源可以廉价获得。此外，使用氢卤酸和有机溶剂从含杂质的(S)-α-卤甲基-3-吡啶甲醇衍生物中分离纯化出(S)-α-卤甲基-3-吡啶甲醇衍生物的氢卤酸盐晶体。
• [EN] COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND OBESITY<br/>[FR] TRAITEMENT COMBINE DU DIABETE ET DE L'OBESITE
  申请人：MERCK & CO., INC.

  公开号：WO1997016189A1

  公开（公告）日：1997-05-09

  (EN) The combination of the $g(b)3 adrenergic receptor agonist Compound A and a compound which modifies feeding behavior (e.g., the OB protein) is useful in the treatment of obesity and diabetes, either as compounds, pharmaceutically acceptable salts, pharmaceutical compoisition ingredients. Methods of treating obesity and diabetes are also described.(FR) L'invention porte sur la combinaison d'un composé A agoniste du récepteur adrénergique $g(b)3 et d'un composé modifiant le comportement alimentaire (par exemple la protéine OB) qui s'avèrent utiles contre l'obésité et le diabète. En utilisant soit la composition elle-même, soit ses sels pharmacocompatibles, soit des préparations pharmaceutiques dont ils sont les principes actifs. L'invention porte également sur les procédés de traitement associés.

  将$g(b)3肾上腺素受体激动剂Compound A与改变饮食行为的化合物（例如OB蛋白质）结合使用，可用于治疗肥胖症和糖尿病，无论是作为化合物、药学上可接受的盐、药物组成成分。还描述了治疗肥胖和糖尿病的方法。
• Process for preparation of (s)-alpha-halomethylpyridine-methanol derivatives
  申请人：——

  公开号：US20040265991A1

  公开（公告）日：2004-12-30

  The present invention provides a process for easily preparing a (S)-&agr;-halomethylpyridine-methanol derivative, which is useful as an intermediate of pharmaceutical products, from inexpensive raw materials. The (S)-&agr;-halomethylpyridine-methanol derivative is prepared by (S)-selectively reducing a 2-haloacetylpyridine derivative using an enzyme source having ability to (S)-selectively reduce a carbonyl group of the 2-haloacetylpyridine derivative, which can be obtained inexpensively. Also, a hydrohalic acid salt of (S)-&agr;-halomethyl-3-pyridine-methanol derivative is isolated and purified as crystal from a (S)-&agr;-halomethyl-3-pyridine-methanol derivative containing impurities using hydrohalic acid and an organic solvent.

  本发明提供了一种从廉价原料中轻松制备(S)-α-卤甲基吡啶甲醇衍生物的方法，该衍生物可用作制药产品的中间体。通过使用具有(S)-选择性还原2-卤乙酰吡啶衍生物的能力的酶源(S)-选择性还原2-卤乙酰吡啶衍生物来制备(S)-α-卤甲基吡啶甲醇衍生物，该酶源可以廉价获得。此外，使用氢卤酸和有机溶剂从含杂质的(S)-α-卤甲基-3-吡啶甲醇衍生物中分离和纯化(S)-α-卤甲基-3-吡啶甲醇衍生物的氢卤酸盐作为晶体。
• FUNKTIONALISIERTE KETON-ALDEHYD-KONDENSATIONSHARZE
  申请人：Evonik Degussa GmbH

  公开号：EP3075788A1

  公开（公告）日：2016-10-05

  Die Erfindung betrifft funktionalisierte Keton-Aldehyd-Kondensationsharze, deren Herstellung und deren Verwendung.

  本发明涉及官能化酮醛缩合树脂、其制备和使用。